400 results on '"Dabrosin, Charlotta"'
Search Results
2. Low-dose acetylsalicylic acid reduces local inflammation and tissue perfusion in dense breast tissue in postmenopausal women
- Author
-
Lundberg, Peter, Abrahamsson, Annelie, Kihlberg, Johan, Tellman, Jens, Tomkeviciene, Ieva, Karlsson, Anette, Kristoffersen Wiberg, Maria, Warntjes, Marcel, and Dabrosin, Charlotta
- Published
- 2024
- Full Text
- View/download PDF
3. Increased matrix stiffness enhances pro-tumorigenic traits in a physiologically relevant breast tissue- monocyte 3D model
- Author
-
Abrahamsson, Annelie, Boroojeni, Fatemeh Rasti, Naeimipour, Sajjad, Reustle, Nina, Selegård, Robert, Aili, Daniel, and Dabrosin, Charlotta
- Published
- 2024
- Full Text
- View/download PDF
4. Breast density is strongly associated with multiparametric magnetic resonance imaging biomarkers and pro-tumorigenic proteins in situ
- Author
-
Lundberg, Peter, Forsgren, Mikael F., Tellman, Jens, Kihlberg, Johan, Rzepecka, Anna, and Dabrosin, Charlotta
- Published
- 2022
- Full Text
- View/download PDF
5. Proteolytic remodeling of 3D bioprinted tumor microenvironments
- Author
-
Rasti Boroojeni, Fatemeh, Naeimipour, Sajjad, Lifwergren, Philip, Abrahamsson, Annelie, Dabrosin, Charlotta, Selegård, Robert, Aili, Daniel, Rasti Boroojeni, Fatemeh, Naeimipour, Sajjad, Lifwergren, Philip, Abrahamsson, Annelie, Dabrosin, Charlotta, Selegård, Robert, and Aili, Daniel
- Abstract
In native tissue, remodeling of the pericellular space is essential for cellular activities and is mediated by tightly regulated proteases. Protease activity is dysregulated in many diseases, including many forms of cancer. Increased proteolytic activity is directly linked to tumor invasion into stroma, metastasis, and angiogenesis as well as all other hallmarks of cancer. Here we show a strategy for 3D bioprinting of breast cancer models using well-defined protease degradable hydrogels that can facilitate exploration of the multifaceted roles of proteolytic extracellular matrix remodeling in tumor progression. We designed a set of bicyclo[6.1.0]nonyne functionalized hyaluronan (HA)-based bioinks cross-linked by azide-modified poly(ethylene glycol) (PEG) or matrix metalloproteinase (MMP) degradable azide-functionalized peptides. Bioprinted structures combining PEG and peptide-based hydrogels were proteolytically degraded with spatial selectivity, leaving non-degradable features intact. Bioprinting of tumor-mimicking microenvironments using bioinks comprising human breast cancer cells (MCF-7) and fibroblast in hydrogels with different susceptibilities to proteolytic degradation shows that MCF-7 proliferation and spheroid size were significantly increased in protease degradable hydrogel compartments, but only in the presence of fibroblasts. In the absence of fibroblasts in the stromal compartment, cancer cell proliferation was reduced and did not differ between degradable and nondegradable hydrogels. The interactions between spatially separated fibroblasts and MCF-7 cells consequently resulted in protease-mediated remodeling of the bioprinted structures and a significant increase in cancer cell spheroid size, highlighting the close interplay between cancer cells and stromal cells in the tumor microenvironment and the influence of proteases in tumor progression., Funding Agencies|Knut and Alice Wallenberg Foundation (KAW) [2016.0231, 2021.0186]; European Research Council [101044665]; Carl Tryggers Stiftelse
- Published
- 2024
- Full Text
- View/download PDF
6. Designing a broad-spectrum integrative approach for cancer prevention and treatment
- Author
-
Block, Keith I, Gyllenhaal, Charlotte, Lowe, Leroy, Amedei, Amedeo, Amin, ARM Ruhul, Amin, Amr, Aquilano, Katia, Arbiser, Jack, Arreola, Alexandra, Arzumanyan, Alla, Ashraf, S Salman, Azmi, Asfar S, Benencia, Fabian, Bhakta, Dipita, Bilsland, Alan, Bishayee, Anupam, Blain, Stacy W, Block, Penny B, Boosani, Chandra S, Carey, Thomas E, Carnero, Amancio, Carotenuto, Marianeve, Casey, Stephanie C, Chakrabarti, Mrinmay, Chaturvedi, Rupesh, Chen, Georgia Zhuo, Chen, Helen, Chen, Sophie, Chen, Yi Charlie, Choi, Beom K, Ciriolo, Maria Rosa, Coley, Helen M, Collins, Andrew R, Connell, Marisa, Crawford, Sarah, Curran, Colleen S, Dabrosin, Charlotta, Damia, Giovanna, Dasgupta, Santanu, DeBerardinis, Ralph J, Decker, William K, Dhawan, Punita, Diehl, Anna Mae E, Dong, Jin-Tang, Dou, Q Ping, Drew, Janice E, Elkord, Eyad, El-Rayes, Bassel, Feitelson, Mark A, Felsher, Dean W, Ferguson, Lynnette R, Fimognari, Carmela, Firestone, Gary L, Frezza, Christian, Fujii, Hiromasa, Fuster, Mark M, Generali, Daniele, Georgakilas, Alexandros G, Gieseler, Frank, Gilbertson, Michael, Green, Michelle F, Grue, Brendan, Guha, Gunjan, Halicka, Dorota, Helferich, William G, Heneberg, Petr, Hentosh, Patricia, Hirschey, Matthew D, Hofseth, Lorne J, Holcombe, Randall F, Honoki, Kanya, Hsu, Hsue-Yin, Huang, Gloria S, Jensen, Lasse D, Jiang, Wen G, Jones, Lee W, Karpowicz, Phillip A, Keith, W Nicol, Kerkar, Sid P, Khan, Gazala N, Khatami, Mahin, Ko, Young H, Kucuk, Omer, Kulathinal, Rob J, Kumar, Nagi B, Kwon, Byoung S, Le, Anne, Lea, Michael A, Lee, Ho-Young, Lichtor, Terry, Lin, Liang-Tzung, Locasale, Jason W, Lokeshwar, Bal L, Longo, Valter D, Lyssiotis, Costas A, MacKenzie, Karen L, Malhotra, Meenakshi, Marino, Maria, Martinez-Chantar, Maria L, and Matheu, Ander
- Subjects
Biomedical and Clinical Sciences ,Oncology and Carcinogenesis ,Cancer ,Rare Diseases ,Precision Medicine ,Aetiology ,5.1 Pharmaceuticals ,Development of treatments and therapeutic interventions ,2.1 Biological and endogenous factors ,Good Health and Well Being ,Antineoplastic Agents ,Phytogenic ,Drug Resistance ,Neoplasm ,Genetic Heterogeneity ,Humans ,Molecular Targeted Therapy ,Neoplasms ,Signal Transduction ,Tumor Microenvironment ,Multi-targeted ,Cancer hallmarks ,Phytochemicals ,Targeted therapy ,Integrative medicine ,Oncology & Carcinogenesis ,Biochemistry and cell biology ,Oncology and carcinogenesis - Abstract
Targeted therapies and the consequent adoption of "personalized" oncology have achieved notable successes in some cancers; however, significant problems remain with this approach. Many targeted therapies are highly toxic, costs are extremely high, and most patients experience relapse after a few disease-free months. Relapses arise from genetic heterogeneity in tumors, which harbor therapy-resistant immortalized cells that have adopted alternate and compensatory pathways (i.e., pathways that are not reliant upon the same mechanisms as those which have been targeted). To address these limitations, an international task force of 180 scientists was assembled to explore the concept of a low-toxicity "broad-spectrum" therapeutic approach that could simultaneously target many key pathways and mechanisms. Using cancer hallmark phenotypes and the tumor microenvironment to account for the various aspects of relevant cancer biology, interdisciplinary teams reviewed each hallmark area and nominated a wide range of high-priority targets (74 in total) that could be modified to improve patient outcomes. For these targets, corresponding low-toxicity therapeutic approaches were then suggested, many of which were phytochemicals. Proposed actions on each target and all of the approaches were further reviewed for known effects on other hallmark areas and the tumor microenvironment. Potential contrary or procarcinogenic effects were found for 3.9% of the relationships between targets and hallmarks, and mixed evidence of complementary and contrary relationships was found for 7.1%. Approximately 67% of the relationships revealed potentially complementary effects, and the remainder had no known relationship. Among the approaches, 1.1% had contrary, 2.8% had mixed and 62.1% had complementary relationships. These results suggest that a broad-spectrum approach should be feasible from a safety standpoint. This novel approach has potential to be relatively inexpensive, it should help us address stages and types of cancer that lack conventional treatment, and it may reduce relapse risks. A proposed agenda for future research is offered.
- Published
- 2015
7. Dietary flaxseed and tamoxifen affect the inflammatory microenvironment in vivo in normal human breast tissue of postmenopausal women
- Author
-
Lindahl, Gabriel, Abrahamsson, Annelie, and Dabrosin, Charlotta
- Subjects
Tamoxifen -- Dosage and administration ,Flaxseed -- Dosage and administration ,Postmenopausal women -- Health aspects ,Breast cancer -- Care and treatment -- Physiological aspects ,Food/cooking/nutrition ,Health - Abstract
Background Anti-oestrogens such as tamoxifen, decrease the risk of breast cancer but are unsuitable for prevention because of their side-effects. Diet modifications may be a breast cancer prevention strategy. Here, we investigated if a diet addition of flaxseed, which can be converted to the phytoestrogen enterolactone by the gut microbiota, exhibited similar effects as tamoxifen on normal human breast tissue in vivo, with special emphasis on inflammatory mediators implicated in cancer progression. Subjects A total of 28 postmenopausal women were included. Thirteen women added 25 g of ground flaxseed per day and 15 were treated with tamoxifen as an adjuvant for early breast cancer for 6 weeks. Microdialysis of normal breast tissue and, as a control, in subcutaneous abdominal fat was performed for sampling of extracellular proteins in vivo before and after exposures. Results Enterolactone levels increased significantly after flaxseed. IL-1Ra and IL-1Ra/IL-1[beta] ratio in the breast increased in a similar fashion after the two different treatments. Flaxseed also increased breast specific levels of IL-1RT2, IL-18 and sST2 and an overall increase of MMP-9. These changes correlated significantly with enterolactone levels. Tamoxifen decreased breast tissue levels of IL-8 and IL-18. None of the treatments induced any changes of IL-1[beta], IL-1RT1, IL-18BP, IL-33, IL-6, IL-6RA, MMP-1, MMP-2 and MMP-3. Conclusions We conclude that dietary flaxseed and tamoxifen exert both similar and different effects, as listed above, on normal breast tissue in vivo and that a relatively modest diet change can induce significant effects on the breast microenvironment., Author(s): Gabriel Lindahl [sup.1] , Annelie Abrahamsson [sup.1] , Charlotta Dabrosin [sup.1] Author Affiliations: (1) Department of Oncology and Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden Introduction [...]
- Published
- 2019
- Full Text
- View/download PDF
8. Breast density and estradiol are associated with distinct different expression patterns of metabolic proteins in normal human breast tissue in vivo
- Author
-
Ekstrand, Jimmy, Abrahamsson, Annelie, Lundberg, Peter, Dabrosin, Charlotta, Ekstrand, Jimmy, Abrahamsson, Annelie, Lundberg, Peter, and Dabrosin, Charlotta
- Abstract
BackgroundBreast density and exposure to sex steroids are major risk factors for breast cancer. The local microenvironment plays an essential role in progression of breast cancer. Metabolic adaption is a major hallmark of cancer. Whether proteins from the extracellular space regulating metabolism are affected in breast cancer, dense breasts or by estrogen exposure are not yet fully elucidated. MethodsWomen with breast cancer, postmenopausal women with normal breast tissue with varying breast density or premenopausal women with breasts exposed to high levels of estradiol were included in the study. Microdialysis was used to collect proteins from the extracellular space in vivo in 73 women; 12 with breast cancer, 42 healthy postmenopausal women with different breast densities, and 19 healthy premenopausal women. Breast density was determined as lean tissue fraction (LTF) using magnetic resonance imaging. Data were evaluated in a murine breast cancer model. We quantified a panel of 92 key proteins regulating metabolism using proximity extension assay. ResultsWe report that 29 proteins were upregulated in human breast cancer. In dense breasts 37 proteins were upregulated and 17 of these were similarly regulated as in breast cancer. 32 proteins correlated with LTF. In premenopausal breasts 19 proteins were up-regulated and 9 down-regulated. Of these, 27 correlated to estradiol, a result that was confirmed for most proteins in experimental breast cancer. Only two proteins, pro-cathepsin H and galanin peptide, were similarly regulated in breast cancer, dense- and estrogen exposed breasts. ConclusionsMetabolic proteins may be targetable for breast cancer prevention. Depending on risk factor, this may, however, require different approaches as breast density and estradiol induce distinct different expression patterns in the breast. Additionally, metabolic proteins from the extracellular space may indeed be further explored as therapeutic targets for breast cancer treatment.
- Published
- 2023
- Full Text
- View/download PDF
9. Adipokines and Vascular Endothelial Growth Factor in Normal Human Breast Tissue in Vivo – Correlations and Attenuation by Dietary Flaxseed
- Author
-
Morad, Vivian, Abrahamsson, Annelie, Kjölhede, Preben, and Dabrosin, Charlotta
- Published
- 2016
- Full Text
- View/download PDF
10. Breast Density and Estradiol Are Major Determinants for Soluble TNF-TNF-R Proteins in vivo in Human Breast Tissue
- Author
-
Ekstrand, Jimmy, Zemmler, Maja, Abrahamsson, Annelie, Lundberg, Peter, Forsgren, Mikael, Dabrosin, Charlotta, Ekstrand, Jimmy, Zemmler, Maja, Abrahamsson, Annelie, Lundberg, Peter, Forsgren, Mikael, and Dabrosin, Charlotta
- Abstract
High mammographic density and exposure to sex steroids are independent risk factors for breast cancer by yet unknown mechanisms. Inflammation is one hallmark of cancer and the tumor necrosis factor family of proteins (TNFSFs) and receptors (TNFRSFs) are key determinants of tissue inflammation. The relationship between TNFSFs/TNFRSFs and breast tissue density or local breast estradiol levels is unknown. We investigated whether TNFSFs and soluble TNFRSFs (sTNFRSFs) are dysregulated in vivo in human breast cancer and dense breast tissue of postmenopausal women. We explored TNFSF/TNFRSF correlations with breast density and estradiol, both locally in the breast and in abdominal subcutaneous (s.c.) fat as a measure of systemic effects. Microdialysis was used for local sampling of in vivo proteins and estradiol in a total of 73 women; 12 with breast cancer, 42 healthy postmenopausal women with different breast densities, and 19 healthy premenopausal women. Breast density was determined as lean tissue fraction (LTF) using magnetic resonance imaging. Microdialysis was also performed in estrogen receptor (ER) positive breast cancer in mice treated with the pure anti-estrogen fulvestrant and tumor tissue was subjected to immunohistochemistry. 23 members of the TNFSF/sTNFRSF families were quantified using proximity extension assay.Our data revealed upregulation of TNFSF10, 13 and 13B, TNFRSF6, 6B, 9, 11A, 11B, 13B, 14, and 19, and TNFR-1 and -2 in ER+ breast cancer in women. In dense breast tissue TNFSF10, 13, and 14, TNFRSF3, 6, 9, 10B, 13B, 14, 19, and TNFR-1 and -2 were upregulated. Certain TNFSFs/TNFRSFs were increased in premenopausal breasts relative to postmenopausal breasts. Furthermore, estradiol correlated with most of the TNFSF/sTNFRSF members, though LTF only correlated with some of the proteins. Several of these associations were breast tissue-specific, as very few correlated with estradiol in abdominal s.c. fat. Estrogen dependent regulations of TNFSF2 (TNF-alpha), Funding: This work was supported by grants to C.D. from the Swedish Cancer Society (2018/464), the Swedish Research Council (2018-02584), LiU-Cancer, and ALF of Linköping University Hospital.
- Published
- 2022
- Full Text
- View/download PDF
11. Increased endostatin generation and decreased angiogenesis via MMP-9 by tamoxifen in hormone dependent ovarian cancer
- Author
-
Bendrik, Christina, Karlsson, Lisa, and Dabrosin, Charlotta
- Published
- 2010
- Full Text
- View/download PDF
12. Platelet Activation In Situ in Breasts at High Risk of Cancer : Relationship with Mammographic Density and Estradiol
- Author
-
Mijic, Sofija, Dabrosin, Charlotta, Mijic, Sofija, and Dabrosin, Charlotta
- Abstract
Context: High mammographic density in postmenopausal women is an independent risk factor for breast cancer by undetermined mechanisms. No preventive therapy for this risk group is available. Activated platelets release growth factors that modulate the microenvironment into a protumorigenic state. Estrogens may affect the risk of breast cancer and platelet function. Whether platelets are activated in situ in breast cancer or in normal breast tissue at high risk of breast cancer and the association to estradiol remains elusive. Objective: To investigate whether platelets are activated in situ in breast cancers and in dense breast tissue of postmenopausal women and explore correlations between estradiol, released platelet factors, and inflammatory proteins. Setting and design: Sampling of in vivo proteins was performed using microdialysis in a total of 71 women: 10 with breast cancer, 42 healthy postmenopausal women with different breast densities, and 19 premenopausal women. Results: Our data demonstrate increased levels of coagulation factors in dense breast tissue similar to that found in breast cancers, indicating excessive platelet activation. Premenopausal breasts exhibited similar levels of coagulation factors as postmenopausal dense breasts. Out of 13 coagulations factors that were upregulated in dense breasts, 5 exhibited significant correlations with estradiol, both locally in the breast and systemically. In breast tissue, positive correlations between coagulation factors and key inflammatory proteins and matrix metalloproteinases were detected. Conclusions: Breast density, not estradiol, is the major determinant of local platelet activation. Inactivation of platelets may be a therapeutic strategy for cancer prevention in postmenopausal women with dense breasts., Funding Agencies|Swedish Cancer SocietySwedish Cancer Society [2018/464]; Swedish Research CouncilSwedish Research CouncilEuropean Commission [2018-02584]; LiU-Cancer; ALF of Linkoping University Hospital
- Published
- 2021
- Full Text
- View/download PDF
13. Estradiol Affects Extracellular Leptin: Adiponectin Ratio in Human Breast Tissue in Vivo
- Author
-
Morad, Vivian, Abrahamsson, Annelie, and Dabrosin, Charlotta
- Published
- 2014
14. MMP-2 and MMP-9 activity is regulated by estradiol and tamoxifen in cultured human breast cancer cells
- Author
-
Nilsson, Ulrika W, Garvin, Stina, and Dabrosin, Charlotta
- Published
- 2007
- Full Text
- View/download PDF
15. Lysine in Combination With Estradiol Promote Dissemination of Estrogen Receptor Positive Breast Cancer via Upregulation of U2AF1 and RPN2 Proteins
- Author
-
Vazquez Rodriguez, Gabriela, Abrahamsson, Annelie, Turkina, Maria V., and Dabrosin, Charlotta
- Subjects
Cancer och onkologi ,lysine ,breast cancer ,Oncology ,microdialysis ,Cancer and Oncology ,dissemination ,zebrafish ,essential amino acids ,Original Research - Abstract
The majority of estrogen receptor positive (ER+) breast cancer (BC) maintain the ER at metastatic sites. Despite anti-estrogen therapy, almost 30% of ER+ BC patients relapse. Thus, new therapeutic targets for ER+ BC are needed. Amino acids (AAs) may affect the metastatic capacity by affecting inflammatory cells. Essential AAs (EAAs) cannot be produced by human cells and might therefore be targetable as therapeutics. Here we sampled extracellular EAAs in vivo by microdialysis in human BC. Mass spectrometry-based proteomics was used to identify proteins affected after EAA and estradiol (E2) exposure to BC cells. Proteins relevant for patient survival were identified, knocked down in BC cells, and metastatic capability was determined in vivo in the transgenic zebrafish model. We found that lysine was the most utilized EAA in human ER+BC in vivo. In zebrafish, lysine in presence of E2 increased neutrophil-dependent dissemination of ER+ BC cells via upregulation of U2AF1 and RPN2 proteins, which both correlated with poor prognosis of ER+ BC patients in clinical databases. Knockdown of U2AF1 and RPN2 decreased the expression of several cell-adhesion molecules resulting in diminished dissemination. Dietary lysine or its related metabolic pathways may be useful therapeutic targets in ER+ BC. Funding Agencies|Swedish Cancer SocietySwedish Cancer Society [2018/464]; Swedish Research CouncilSwedish Research Council [2018-02584]; LiU-Cancer; ALF of Linkoping University Hospital
- Published
- 2020
16. Estradiol increases VEGF in human breast studied by whole-tissue culture
- Author
-
Garvin, Stina, Nilsson, Ulrika W., Huss, Fredrik R. M., Kratz, Gunnar, and Dabrosin, Charlotta
- Published
- 2006
- Full Text
- View/download PDF
17. Postmenopausal Dense Breasts Maintain Premenopausal Levels of GH and Insulin-like Growth Factor Binding Proteins in Vivo
- Author
-
Dabrosin, Nina, Dabrosin, Charlotta, Dabrosin, Nina, and Dabrosin, Charlotta
- Abstract
Context: Dense breast tissue is associated with 4 to 6 times higher risk of breast cancer by poorly understood mechanisms. No preventive therapy for this high-risk group is available. After menopause, breast density decreases due to involution of the mammary gland. In dense breast tissue, this process is haltered by undetermined biological actions. Growth hormone (GH) and insulin-like binding proteins (IGFBPs) play major roles in normal mammary gland development, but their roles in maintaining breast density are unknown. Objective: To reveal in vivo levels of GH, IGFBPs, and other pro-tumorigenic proteins in the extracellular microenvironment in breast cancer, in normal breast tissue with various breast density in postmenopausal women, and premenopausal breasts. We also sought to determine possible correlations between these determinants. Setting and Design: Microdialysis was used to collect extracellular in vivo proteins intratumorally from breast cancers before surgery and from normal human breast tissue from premenopausal women and postmenopausal women with mammographic dense or nondense breasts. Results: Estrogen receptor positive breast cancers exhibited increased extracellular GH (P <.01). Dense breasts of postmenopausal women exhibited similar levels of GH as premenopausal breasts and significantly higher levels than in nondense breasts (P <.001). Similar results were found for IGFBP-1, -2, -3, and -7 (P <.01) and for IGFBP-6 (P <.05). Strong positive correlations were revealed between GH and IGFBPs and pro-tumorigenic matrix metalloproteinases, urokinase-type plasminogen activator, Interleukin 6, Interleukin 8, and vascular endothelial growth factor in normal breast tissue. Conclusions: GH pathways may be targetable for cancer prevention therapeutics in postmenopausal women with dense breast tissue., Funding Agencies|Swedish Cancer SocietySwedish Cancer Society [2018/464]; Swedish Research CouncilSwedish Research Council [2018-02584]; LiU-Cancer; ALF of Linkoping University Hospital
- Published
- 2020
- Full Text
- View/download PDF
18. Fulvestrant-Mediated Attenuation of the Innate Immune Response Decreases ER+ Breast Cancer Growth In Vivo More Effectively than Tamoxifen
- Author
-
Abrahamsson, Annelie, Vazquez Rodriguez, Gabriela, Dabrosin, Charlotta, Abrahamsson, Annelie, Vazquez Rodriguez, Gabriela, and Dabrosin, Charlotta
- Abstract
Although blocking estrogen-dependent signaling is a cornerstone of adjuvant treatment for breast cancer, 25% of patients experience recurrent disease. Stroma events including innate immune responses are key in cancer progression. How different estrogen receptor (ER)-targeting therapies, including the partial agonist tamoxifen and the pure antagonist fulvestrant, affect the tumor stroma has not yet been elucidated. Fulvestrant is used in only postmenopausal patients, and its effects in the presence of estradiol remain undetermined. Here we observe that fulvestrant decreases ER+ breast cancer growth compared with tamoxifen in the presence of physiologic levels of estradiol in human breast cancer in nude mice and in murine breast cancer in immune-competent mice. Fulvestrant significantly inhibited macrophage and neutrophil infiltration in both models. These effects were corroborated in a zebrafish model where fulvestrant inhibited neutrophil- and macrophage-dependent cancer cell dissemination more effectively than tamoxifen. A comprehensive analysis of 234 human proteins released into the cancer microenvironment by the cancer cells sampled via microdialysis in vivo revealed that 38 proteins were altered following both treatments; 25 of these proteins were associated with immune response and were altered by fulvestrant only. Compared with tamoxifen, fulvestrant significantly affected inflammatory proteins released by murine stroma cells. Importantly, in vivo microdialysis of human ER+ breast cancer revealed that the majority of affected proteins in murine models were upregulated in patients. Together, these results suggest that fulvestrant targets ER+ breast cancer more effectively than tamoxifen even in the presence of estradiol, mainly by attenuation of the innate immune response. Significance: These findings demonstrate novel effects of the pure antiestrogen fulvestrant in ERthorn breast cancer and evaluate its effects under physiologic levels of estradiol, represent, Funding Agencies|Swedish Cancer SocietySwedish Cancer Society [2018/464]; Swedish Research CouncilSwedish Research Council [2018-02584]; LiU-Cancer; ALF of Linkoping University Hospital
- Published
- 2020
- Full Text
- View/download PDF
19. Sex steroid regulation of angiogenesis in breast tissue
- Author
-
Dabrosin, Charlotta
- Published
- 2005
- Full Text
- View/download PDF
20. Decreased secretion of Cathepsin D in breast cancer in vivo by tamoxifen: Mediated by the mannose-6-phosphate/IGF-II receptor?
- Author
-
Dabrosin, Charlotta, Johansson, Ann-Charlotte, and Öllinger, Karin
- Published
- 2004
- Full Text
- View/download PDF
21. Increase of Free Insulin-Like Growth Factor-1 in Normal Human Breast in vivo Late in the Menstrual Cycle
- Author
-
Dabrosin, Charlotta
- Published
- 2003
- Full Text
- View/download PDF
22. Estradiol Promotes Growth and Angiogenesis in Polyoma Middle T Transgenic Mouse Mammary Tumor Explants
- Author
-
Dabrosin, Charlotta, Palmer, Kay, Muller, William J., and Gauldie, Jack
- Published
- 2003
- Full Text
- View/download PDF
23. Estradiol, Tamoxifen, and Flaxseed Alter IL-1β and IL-1Ra Levels in Normal Human Breast Tissue in Vivo
- Author
-
Abrahamsson, Annelie, Morad, Vivian, Saarinen, Niina M., and Dabrosin, Charlotta
- Published
- 2012
24. Broad targeting of angiogenesis for cancer prevention and therapy
- Author
-
Wang, Zongwei, Dabrosin, Charlotta, Yin, Xin, Fuster, Mark M., Arreola, Alexandra, Rathmell, W. Kimryn, Generali, Daniele, Nagaraju, Ganji P., El-Rayes, Bassel, Ribatti, Domenico, Chen, Yi Charlie, Honoki, Kanya, Fujii, Hiromasa, Georgakilas, Alexandros G., Nowsheen, Somaira, Amedei, Amedeo, Niccolai, Elena, Amin, Amr, Ashraf, S. Salman, Helferich, Bill, Yang, Xujuan, Guha, Gunjan, Bhakta, Dipita, Ciriolo, Maria Rosa, Aquilano, Katia, Chen, Sophie, Halicka, Dorota, Mohammed, Sulma I., Azmi, Asfar S., Bilsland, Alan, Keith, W. Nicol, Jensen, Lasse D., Wang, Zongwei, Dabrosin, Charlotta, Yin, Xin, Fuster, Mark M., Arreola, Alexandra, Rathmell, W. Kimryn, Generali, Daniele, Nagaraju, Ganji P., El Rayes, Bassel, Ribatti, Domenico, Chen, Yi Charlie, Honoki, Kanya, Fujii, Hiromasa, Georgakilas, Alexandros G., Nowsheen, Somaira, Amedei, Amedeo, Niccolai, Elena, Amin, Amr, Ashraf, S. Salman, Helferich, Bill, Yang, Xujuan, Guha, Gunjan, Bhakta, Dipita, Ciriolo, Maria Rosa, Aquilano, Katia, Chen, Sophie, Halicka, Dorota, Mohammed, Sulma I., Azmi, Asfar S., Bilsland, Alan, Keith, W. Nicol, and Jensen, Lasse D.
- Subjects
Cancer och onkologi ,Cancer Research ,Neovascularization, Pathologic ,Anti-angiogenic ,Phytochemicals ,Angiogenesis Inhibitors ,Review ,Phytochemical ,Antineoplastic Agents, Phytogenic ,Angiogenesis Cancer Phytochemicals Treatment Anti-angiogenic ,Treatment ,Angiogenesi ,Angiogenesis ,Cancer ,Cancer and Oncology ,Neoplasms ,Blood Vessels ,Humans ,Immunotherapy ,Settore BIO/10 ,Cell Proliferation - Abstract
Deregulation of angiogenesis - the growth of new blood vessels from an existing vasculature - is a main driving force in many severe human diseases including cancer. As such, tumor angiogenesis is important for delivering oxygen and nutrients to growing tumors, and therefore considered an essential pathologic feature of cancer, while also playing a key role in enabling other aspects of tumor pathology such as metabolic deregulation and tumor dissemination/metastasis. Recently, inhibition of tumor angiogenesis has become a clinical anti-cancer strategy in line with chemotherapy, radiotherapy and surgery, which underscore the critical importance of the angiogenic switch during early tumor development. Unfortunately the clinically approved anti-angiogenic drugs in use today are only effective in a subset of the patients, and many who initially respond develop resistance over time. Also, some of the anti-angiogenic drugs are toxic and it would be of great importance to identify alternative compounds, which could overcome these drawbacks and limitations of the currently available therapy. Finding "the most important target" may, however, prove a very challenging approach as the tumor environment is highly diverse, consisting of many different cell types, all of which may contribute to tumor angiogenesis. Furthermore, the tumor cells themselves are genetically unstable, leading to a progressive increase in the number of different angiogenic factors produced as the cancer progresses to advanced stages. As an alternative approach to targeted therapy, options to broadly interfere with angiogenic signals by a mixture of non-toxic natural compound with pleiotropic actions were viewed by this team as an opportunity to develop a complementary anti-angiogenesis treatment option. As a part of the "Halifax Project" within the "Getting to know cancer" framework, we have here, based on a thorough review of the literature, identified 10 important aspects of tumor angiogenesis and the pathological tumor vasculature which would be well suited as targets for anti-angiogenic therapy: (1) endothelial cell migration/tip cell formation, (2) structural abnormalities of tumor vessels, (3) hypoxia, (4) lymphangiogenesis, (5) elevated interstitial fluid pressure, (6) poor perfusion, (7) disrupted circadian rhythms, (8) tumor promoting inflammation, (9) tumor promoting fibroblasts and (10) tumor cell metabolism/acidosis. Following this analysis, we scrutinized the available literature on broadly acting anti-angiogenic natural products, with a focus on finding qualitative information on phytochemicals which could inhibit these targets and came up with 10 prototypical phytochemical compounds: (1) oleic acid, (2) tripterine, (3) silibinin, (4) curcumin, (5) epigallocatechin-gallate, (6) kaempferol, (7) melatonin, (8) enterolactone, (9) withaferin A and (10) resveratrol. We suggest that these plant-derived compounds could be combined to constitute a broader acting and more effective inhibitory cocktail at doses that would not be likely to cause excessive toxicity. All the targets and phytochemical approaches were further cross-validated against their effects on other essential tumorigenic pathways (based on the "hallmarks" of cancer) in order to discover possible synergies or potentially harmful interactions, and were found to generally also have positive involvement in/effects on these other aspects of tumor biology. The aim is that this discussion could lead to the selection of combinations of such anti-angiogenic compounds which could be used in potent anti-tumor cocktails, for enhanced therapeutic efficacy, reduced toxicity and circumvention of single-agent anti-angiogenic resistance, as well as for possible use in primary or secondary cancer prevention strategies. Funding agencies: Swedish Society for Medical Research; Goesta Fraenkel Foundation; Ake Wibergs Foundation; Ollie och Elof Ericssons Foundation; Karolinska Institute; Linkoping University; University of Glasgow; Beatson Oncology Center Fund; Cancer Research UK grant
- Published
- 2015
- Full Text
- View/download PDF
25. Estrogen-induced angiogenic factors derived from stromal and cancer cells are differently regulated by enterolactone and genistein in human breast cancer in vivo
- Author
-
Saarinen, Niina M., Abrahamsson, Annelie, and Dabrosin, Charlotta
- Published
- 2010
- Full Text
- View/download PDF
26. Downregulation of tumor suppressive microRNAs in vivo in dense breast tissue of postmenopausal women
- Author
-
Abrahamsson, Annelie, Capodanno, Alessandra, Rzepecka, Anna, and Dabrosin, Charlotta
- Subjects
Cancer och onkologi ,mammary gland ,microdialysis ,mammography ,extracellular miRNA ,inflammation ,Cancer and Oncology ,skin and connective tissue diseases ,Research Paper - Abstract
Women with dense breast tissue on mammography are at higher risk of developing breast cancer but the underlying mechanisms are not well understood. De-regulation of microRNAs (miRNAs) has been associated with the onset of breast cancer. miRNAs in the extracellular space participate in the regulation of the local tissue microenvironment. Here, we recruited 39 healthy postmenopausal women attending their mammography-screen that were assessed having extreme dense or entirely fatty breasts (nondense). Microdialysis was performed in breast tissue and a reference catheter was inserted in abdominal subcutaneous fat for local sampling of extracellular compounds. Three miRNAs, associated with tumor suppression, miR-193b, miR-365a, and miR-452 were significantly down-regulated in dense breast tissue compared with nondense breast tissue. In addition, miR-452 exhibited significant negative correlations with several pro-inflammatory cytokines in vivo, which was confirmed in vitro by overexpression of miR-452 in breast cancer cells. No differences were found of miR-21, -29a, -30c, 146a, -148a, -203, or -451 in breast tissue and no miRs were different in plasma. Extracellular miRNAs may be among factors that should be included in studies of novel prevention strategies for breast cancer. Funding Agencies|Swedish Cancer Society [2015/309]; Swedish Research Council [2013-2457]; LiU-Cancer; ALF of Linkoping University Hospital
- Published
- 2017
27. Tamoxifen decreases extracellular TGF-β1 secreted from breast cancer cells — A post-translational regulation involving matrix metalloproteinase activity
- Author
-
Nilsson, Ulrika W, Jönsson, Jill A, and Dabrosin, Charlotta
- Published
- 2009
- Full Text
- View/download PDF
28. Increased Extracellular Osteopontin Levels in Normal Human Breast Tissue at High Risk of Developing Cancer and Its Association With Inflammatory Biomarkers in situ
- Author
-
Lindahl, Gabriel, Rzepecka, Anna, and Dabrosin, Charlotta
- Subjects
Cancer Research ,Cancer och onkologi ,Oncology ,tamoxifen ,stomatognathic system ,inflammation ,microdialysis ,Cancer and Oncology ,flaxseed ,enterolactone ,Original Research - Abstract
Mammographic breast density is a strong independent risk factor for breast cancer (BC), but the molecular mechanisms behind this risk is yet undetermined and prevention strategies for these women are lacking. The anti-estrogen tamoxifen may reduce the risk of BC but this treatment is associated with severe side effects. Thus, other means for BC prevention, such as diet interventions, need to be developed. Osteopontin (OPN) is a major mediator of inflammation which is key in carcinogenesis. OPN may be cleaved by proteases in the tissue and cleaved OPN may in turn induce an inflammatory cascade in the extracellular microenvironment. We aimed to determine if extracellular OPN was altered in BC and in normal breast tissue with different densities and if tamoxifen or a diet of flaxseed could modify OPN levels. The study comprised 103 women; 13 diagnosed with BC, 42 healthy post-menopausal women with different breast densities at their mammography screen, and 34 post-menopausal women who added 25 g of ground flaxseed/day or were treated with tamoxifen 20 mg/day and were investigated before and after 6 weeks of exposure. Additionally, 10 premenopausal women who added flaxseed for one menstrual cycle and four who were investigated in two unexposed consecutive luteal phases of the menstrual cycle. Microdialysis was used to sample extracellular proteins in vivo in breast tissue and proteins were quantified using a multiplex proximity extension assay. We found that, similar to BC, extracellular in vivo OPN levels were significantly increased in dense breast tissue. Additionally, significant correlations were found between OPN and chemokine (C-X-C motif) ligand (CXCL)-1, -8, -9, -10, and - 11, interleukin-6, vascular endothelial growth factor, matrix metalloproteinase (MMP)-1, - 2, -3, 7, and -12 and urokinase-type plasminogen activator whereas no correlations were found with MMP-9, chemokine (C-C motif) ligand (CCL)-2, and -5. Estradiol did not affect OPN levels in breast tissue. None of the interventions altered OPN levels. The pro-tumorigenic protein OPN may indeed be a molecular target for BC prevention in women with increased breast density but other means than tamoxifen or flaxseed i.e., more potent anti-inflammatory approaches, need to be evaluated for this purpose. Funding Agencies|Swedish Cancer Society [2018/464]; Swedish Research Council [2018-02584]; LiU-Cancer; ALF of Linkoping University Hospital
- Published
- 2019
29. Association between ulcerative growth and hypoxia inducible factor-1α polymorphisms in colorectal cancer patients
- Author
-
Fransén, Karin, Fenech, Matthew, Fredrikson, Mats, Dabrosin, Charlotta, and Söderkvist, Peter
- Published
- 2006
- Full Text
- View/download PDF
30. Variability of glutathione during the menstrual cycle—due to estrogen effects on hepatocytes?
- Author
-
Dabrosin, Charlotta and Öllinger, Karin
- Published
- 2004
- Full Text
- View/download PDF
31. Variability of Vascular Endothelial Growth Factor in Normal Human Breast Tissue in Vivo during the Menstrual Cycle
- Author
-
Dabrosin, Charlotta
- Published
- 2003
32. Adipocytes Promote Early Steps of Breast Cancer Cell Dissemination via Interleukin-8
- Author
-
Vazquez Rodriguez, Gabriela, Abrahamsson, Annelie, Jensen, Lasse Dahl Ejby, and Dabrosin, Charlotta
- Subjects
Vascular Endothelial Growth Factor A ,microdialysis ,Immunology ,Breast Neoplasms ,angiogenesis ,breast cancer ,Antineoplastic Agents, Immunological ,Cell Movement ,Cell Line, Tumor ,Adipocytes ,Animals ,Humans ,Neoplasm Metastasis ,skin and connective tissue diseases ,Zebrafish ,Original Research ,Aged ,Aged, 80 and over ,Neovascularization, Pathologic ,Interleukin-8 ,Middle Aged ,Xenograft Model Antitumor Assays ,Tumor Burden ,Disease Models, Animal ,Neutrophil Infiltration ,inflammation ,Cytokines ,Female ,Neoplasm Grading ,Biomarkers - Abstract
Fat is a major tissue component in human breast cancer (BC). Whether breast adipocytes (BAd) affect early stages of BC metastasis is yet unknown. BC progression is dependent on angiogenesis and inflammation, and interleukin-8 (IL-8) and vascular endothelial growth factor (VEGF) are key regulators of these events. Here, we show that BAd increased the dissemination of estrogen receptor positive BC cells (BCC) in vivo in the zebrafish model of metastasis, while dissemination of the more aggressive and metastatic BCC such as estrogen receptor negative was unaffected. While anti-VEGF and anti-IL-8 exhibited equal inhibition of angiogenesis at the primary tumor site, anti-IL-8 reduced BCC dissemination whereas anti-VEGF had minor effects on this early metastatic event. Mechanistically, overexpression of cell-adhesion molecules in BCC and neutrophils via IL-8 increased the dissemination of BCC. Importantly, the extracellular in vivo levels of IL-8 were 40-fold higher than those of VEGF in human BC. Our results suggest that IL-8 is a clinical relevant and promising therapeutic target for human BC.
- Published
- 2018
33. Equal Pro-inflammatory Profiles of CCLs, CXCLs, and Matrix Metalloproteinases in the Extracellular Microenvironment In Vivo in Human Dense Breast Tissue and Breast Cancer
- Author
-
Abrahamsson, Annelie, Rzepecka, Anna, and Dabrosin, Charlotta
- Subjects
Immunology ,Mikrobiologi inom det medicinska området ,Immunology and Allergy ,chemokines ,cytokines ,mammary gland ,microdialysis ,microenvironment ,skin and connective tissue diseases ,Microbiology in the medical area - Abstract
The inflammatory microenvironment affects breast cancer progression. Proteins that govern the inflammatory response are secreted into the extracellular space, but this compartment still needs to be characterized in human breast tissues in vivo. Dense breast tissue is a major risk factor for breast cancer by yet unknown mechanisms and no non-toxic prevention for these patients exists. Here, we used the minimal invasive technique of microdialysis for sampling of extracellular proteins in live tissues in situ in breast cancers of women before surgery and in healthy women having dense or non-dense breast tissue on mammography. Proteins were profiled using a proximity extension assay. Out of the 32 proteins assessed, 26 exhibited similar profiles in breast cancers and dense breast tissues; CCL-4, -7, -8, -11, -15, -16, -22, -23, and -25, CXCL-5, -8, -9, -16 as well as sIL-6R, IL-18, vascular endothelial growth factor, TGF-a, fibroblast growth factor 19, matrix metalloproteinase (MMP)-1, -2, -3, and urokinase-type plasminogen activator were all increased, whereas CCL-3, CX3CL1, hepatocyte growth factor, and MMP-9 were unaltered in the two tissues. CCL-19 and -24, CXCL-1 and -10, and IL-6 were increased in dense breast tissue only, whereas IL-18BP was increased in breast cancer only. Our results provide novel insights in the inflammatory microenvironment in human breast cancer in situ and define potential novel therapeutic targets. Additionally, we show previously unrecognized similarities of the pro-inflammatory microenvironment in dense breast tissue and breast cancer in vivo suggesting that anti-inflammatory breast cancer prevention trials for women with dense breast tissue may be feasible.
- Published
- 2018
34. In vivo measurement of tumor estradiol and Vascular Endothelial Growth Factor in breast cancer patients
- Author
-
Dabrosin Charlotta and Garvin Stina
- Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background Angiogenesis, crucial for tumor progression, is a process regulated in the tissue micro-environment. Vascular endothelial growth factor (VEGF) is a potent stimulatory factor of angiogenesis and a negative prognostic indicator of breast cancer. VEGF is biologically active in the extracellular space and hitherto, there has been a lack of techniques enabling sampling of angiogenic molecules such as VEGF in situ. The majority of breast cancers are estrogen-dependent, and estrogen has been shown to regulate VEGF in normal breast tissue and experimental breast cancer. We investigated if microdialysis may be applicable in human breast cancer for sampling of extracellular VEGF in situ and to explore if there is an association with local estradiol and VEGF levels in normal and cancerous breast tissue. Methods Microdialysis was used to sample VEGF and estradiol in tumors and adjacent normal breast tissue in postmenopausal breast cancer patients. VEGF and estradiol were also measured in plasma, and immunohistochemical staining for VEGF was performed on tumor sections. Results We show that in vivo levels of extracellular VEGF were significantly higher in breast cancer tumors than in normal adjacent breast tissue. There was a significant positive correlation between estradiol and extracellular VEGF in normal breast tissue. However, no correlation was detected between estradiol and VEGF in tumors or between tumor VEGF and plasma VEGF. Conclusion We conclude that VEGF and estradiol correlates significantly in normal breast tissue. Microdialysis may be used to provide novel insight in breast tumor biology and the regulation of molecules in the extracellular space of human breast tumors in vivo.
- Published
- 2008
- Full Text
- View/download PDF
35. Increased nutrient availability in dense breast tissue of postmenopausal women in vivo
- Author
-
Abrahamsson, Annelie, Rzepecka, Anna, and Dabrosin, Charlotta
- Subjects
Vascular Endothelial Growth Factor A ,Cancer och onkologi ,Middle Aged ,Article ,Postmenopause ,Glucose ,Cancer and Oncology ,Humans ,Female ,Breast ,Lactic Acid ,Amino Acids ,skin and connective tissue diseases ,Adiposity ,Aged ,Breast Density - Abstract
Metabolic reprogramming is a hallmark of cancer. Nutrient availability in the tissue microenvironment determines cellular events and may play a role in breast carcinogenesis. High mammographic density is an independent risk factor for breast cancer. Whether nutrient availability differs in normal breast tissues with various densities is unknown. Therefore we investigated whether breast tissues with various densities exhibited differences in nutrient availability. Healthy postmenopausal women from the regular mammographic screening program who had either predominantly fatty breast tissue (nondense), n = 18, or extremely dense breast tissue (dense), n = 20, were included. Microdialysis was performed for the in vivo sampling of amino acids (AAs), analyzed by ultra-high performance liquid chromatography with tandem mass spectroscopy, glucose, lactate and vascular endothelial growth factor (VEGF) in breast tissues and, as a control, in abdominal subcutaneous (s.c.) fat. We found that dense breast tissue exhibited significantly increased levels of 20 proteinogenic AAs and that 18 of these AAs correlated significantly with VEGF. No differences were found in the s.c. fat, except for one AA, suggesting tissue-specific alterations in the breast. Glucose and lactate were unaltered. Our findings provide novel insights into the biology of dense breast tissue that may be explored for breast cancer prevention strategies. Funding Agencies|Swedish Cancer Society [2015/309]; Swedish Research Council [2013-2457]; LiU-Cancer; Linkoping University Hospital
- Published
- 2017
- Full Text
- View/download PDF
36. Estradiol promotes breast cancer cell migration via recruitment and activation of neutrophils
- Author
-
Vazquez Rodriguez, Gabriela, Abrahamsson, Annelie, Jensen, Lasse, Dabrosin, Charlotta, Vazquez Rodriguez, Gabriela, Abrahamsson, Annelie, Jensen, Lasse, and Dabrosin, Charlotta
- Abstract
Estradiol (E2) plays a key role in breast cancer progression. Most breast cancer recurrences express the estrogen receptor (ER), but nearly 50% of patients are resistant to antiestrogen therapy. Novel therapeutic targets of ER-positive breast cancers are needed. Protumoral neutrophils expressing the lymphocyte function-associated antigen 1 (LFA-1) integrin may mediate cancer metastasis, and TGFβ1 is the major chemoattractant for neutrophils. The role of E2 in neutrophil–ER+ breast cancer cell interactions is unknown. We studied this in vivo using murine breast cancers in immunocompetent mice and human breast cancers in nude mice. Cell dissemination was evaluated in a zebrafish model, and microdialysis of breast cancer patients was performed. In vitro studies were done with mammosphere cultures of breast cancer cells and human neutrophils. We found that E2 increased the number of LFA-1+ neutrophils recruited to the invasive edge of mouse tumors, increased TGFβ1 secretion and promoted neutrophil infiltration in mammospheres, and induced overexpression of LFA-1 in neutrophils. In zebrafish, in the presence of E2, neutrophils increased dissemination of ER+ breast cancer cells via LFA-1 and TGFβ1, thus causing noninvasive cancer cells to be highly metastatic. Time-lapse imaging in zebrafish revealed close interactions of neutrophils with cancer cells, which drove breast cancer metastasis. We also found that extracellular TGFβ1 was overproduced in human breast cancer tissue compared with adjacent normal breast tissue. Thus, E2 can regulate immune/cancer cell interactions in tumor microenvironments. Our results indicate that extracellular TGFβ1 is a relevant target in human breast cancer., Funding agencies: Swedish Cancer Society [2015/309]; Swedish Research Council [2013-2457]; LiU-Cancer; Research Funds of Linkoping University Hospital
- Published
- 2017
- Full Text
- View/download PDF
37. Fulvestrant inhibits growth of triple negative breast cancer and synergizes with tamoxifen in ER alpha positive breast cancer by up-regulation of ER beta
- Author
-
Mishra, Ameet K., Abrahamsson, Annelie, Dabrosin, Charlotta, Mishra, Ameet K., Abrahamsson, Annelie, and Dabrosin, Charlotta
- Abstract
The estrogen receptor-alpha (ER alpha) is used as a predictive marker for antiestrogen therapy in breast cancer patients. In addition to aromatase inhibitors, ER alpha can be targeted at the receptor level using the receptor modulator tamoxifen or by the pure anti-estrogen fulvestrant. The role of the second ER, ER-beta (ER beta), as a therapeutic target or prognostic marker in breast cancer is still elusive. Hitherto, it is not known if ER alpha+/ER beta+ breast cancers would benefit from a treatment strategy combining tamoxifen and fulvestrant or if fulvestrant exert any therapeutic effects in ER alpha-/ER beta+ breast cancer. Here, we report that fulvestrant up-regulated ER beta in ER alpha+/ER beta+ breast cancer and in triple negative ER beta+ breast cancers (ER alpha-/ER beta+). In ER alpha+/ER beta+ breast cancer, a combination therapy of tamoxifen and fulvestrant significantly reduced tumor growth compared to either treatment alone both in vivo and in vitro. In ER alpha-/ER beta+ breast cancer fulvestrant had potent effects on cancer growth, in vivo as well as in vitro, and this effect was dependent on intrinsically expressed levels of ER beta. The role of ER beta was further confirmed in cells where ER beta was knocked-in or knocked-down. Inhibition of DNA methyltransferase (DNMT) increased the levels of ER beta and fulvestrant exerted similar potency on DNMT activity as the DNMT inhibitor decitabine. We conclude that fulvestrant may have therapeutic potential in additional groups of breast cancer patients; i) in ER alpha+/ER beta+ breast cancer where fulvestrant synergizes with tamoxifen and ii) in triple negative/ER beta+ breast cancer patients, a subgroup of breast cancer patients with poor prognosis., Funding Agencies|Swedish Cancer Society; Swedish Research Council [2013-2457]; LiU-Cancer; Research Funds of Linkoping University Hospital
- Published
- 2016
- Full Text
- View/download PDF
38. Dense breast tissue in postmenopausal women is associated with a pro-inflammatory microenvironment in vivo
- Author
-
Abrahamsson, Annelie, Rzepecka, Anna, Romu, Thobias, Borga, Magnus, Dahlqvist Leinhard, Olof, Lundberg, Peter, Kihlberg, Johan, Dabrosin, Charlotta, Abrahamsson, Annelie, Rzepecka, Anna, Romu, Thobias, Borga, Magnus, Dahlqvist Leinhard, Olof, Lundberg, Peter, Kihlberg, Johan, and Dabrosin, Charlotta
- Abstract
Inflammation is one of the hallmarks of carcinogenesis. High mammographic density has been associated with increased risk of breast cancer but the mechanisms behind are poorly understood. We evaluated whether breasts with different mammographic densities exhibited differences in the inflammatory microenvironment.Postmenopausal women attending the mammography-screening program were assessed having extreme dense, n = 20, or entirely fatty breasts (nondense), n = 19, on their regular mammograms. Thereafter, the women were invited for magnetic resonance imaging (MRI), microdialysis for the collection of extracellular molecules in situ and a core tissue biopsy for research purposes. On the MRI, lean tissue fraction (LTF) was calculated for a continuous measurement of breast density. LTF confirmed the selection from the mammograms and gave a continuous measurement of breast density. Microdialysis revealed significantly increased extracellular in vivo levels of IL-6, IL-8, vascular endothelial growth factor, and CCL5 in dense breast tissue as compared with nondense breasts. Moreover, the ratio IL-1Ra/IL-1 was decreased in dense breasts. No differences were found in levels of IL-1, IL-1Ra, CCL2, leptin, adiponectin, or leptin:adiponectin ratio between the two breast tissue types. Significant positive correlations between LTF and the pro-inflammatory cytokines as well as between the cytokines were detected. Stainings of the core biopsies exhibited increased levels of immune cells in dense breast tissue.Our data show that dense breast tissue in postmenopausal women is associated with a pro-inflammatory microenvironment and, if confirmed in a larger cohort, suggests novel targets for prevention therapies for women with dense breast tissue., Funding Agencies|Swedish Cancer Society [2015/309]; Swedish Research Council [2013-2457]; LiU-Cancer; Research Funds of Linkoping University Hospital
- Published
- 2016
- Full Text
- View/download PDF
39. Correlation between vascular endothelial growth factor and leptin in normal human breast tissue in vivo
- Author
-
Morad, Vivian, Abrahamsson, Annelie, Kjölhede, Preben, Dabrosin, Charlotta, Morad, Vivian, Abrahamsson, Annelie, Kjölhede, Preben, and Dabrosin, Charlotta
- Abstract
Introduction: Events in the microenvironment are important for carcinogenesis of the breast. Adipocytes, which produce adipokines with paracrine effects, are the most abundant cell type in breast tissue. Exposure to sex steroids affects the risk of breast cancer. It has previously been shown that estrogen regulates the extracellular levels of leptin, adiponectin, IL-1β, and VEGF in normal human breast tissue in vivo. Objective: We aimed to determine if there were any relationships between leptin, adiponectin, IL-1β, and/or VEGF in normal human breast tissue in vivo and to elucidate the role of adipocytes in the regulation of these factors. Design and methods: Microdialysis was used to sample proteins of normal human breast tissue and abdominal subcutaneous (s.c.) fat in situ in pre-and postmenopausal women. An in vitro co-culture model of breast cancer cells and primary mature human adipocytes was used. Results: In vivo, in normal breast tissue, significant positive correlations between VEGF and leptin, and VEGF and leptin/adiponectin ratio were detected. No correlations were found in s.c. abdominal fat tissue. Co-culture of adipocytes and breast cancer cells per se increased the secretion of VEGF and leptin and enhanced the effects of estradiol compared to culture of either cell type alone. In vitro, inhibition of VEGF diminished the release of leptin while inhibition of leptin had no influence on VEGF secretion. In breast tissue, significant correlations between IL-1β and leptin and VEGF were revealed. Conclusions: Our results suggest that VEGF regulates leptin in normal human breast tissue. Moreover, physical contact between adipocytes and breast cancer cells, induces phenotypic changes and enhances the effects of estradiol. These mechanisms may be involved in breast cancer progression.
- Published
- 2015
40. Designing a broad-spectrum integrative approach for cancer prevention and treatment
- Author
-
Block, Keith I., Gyllenhaal, Charlotte, Lowe, Leroy, Amedei, Amedeo, Ruhul Amin, A. R. M., Amin, Amr, Aquilano, Katia, Arbiser, Jack, Arreola, Alexandra, Arzumanyan, Alla, Salman Ashraf, S., Azmi, Asfar S., Benencia, Fabian, Bhakta, Dipita, Bilsland, Alan, Bishayeen, Anupam, Blain, Stacy W., Block, Penny B., Boosani, Chandra S., Carey, Thomas E., Carnero, Amancio, Carotenuto, Marianeve, Casey, Stephanie C., Chakrabarti, Mrinmay, Chaturvedi, Rupesh, Zhuo Chen, Georgia, Chenx, Helen, Chen, Sophie, Charlie Chen, Yi, Choi, Beom K., Rosa Ciriolo, Maria, Coley, Helen M., Collins, Andrew R., Connell, Marisa, Crawford, Sarah, Curran, Colleen S., Dabrosin, Charlotta, Damia, Giovanna, Dasgupta, Santanu, DeBerardinis, Ralph J., Decker, William K., Dhawan, Punita, Diehl, Anna Mae E., Dong, Jin-Tang, Ping Dou, Q., Drew, Janice E., Elkord, Eyad, El-Rayes, Bassel, Feitelson, Mark A., Felsher, Dean W., Ferguson, Lynnette R., Fimognari, Carmela, Firestone, Gary L., Frezza, Christian, Fujii, Hiromasa, Fuster, Mark M., Generali, Daniele, Georgakilas, Alexandros G., Gieseler, Frank, Gilbertson, Michael, Green, Michelle F., Grue, Brendan, Guha, Gunjan, Halicka, Dorota, Helferich, William G., Heneberg, Petr, Hentosh, Patricia, Hirschey, Matthew D., Hofseth, Lorne J., Holcombe, Randall F., Honoki, Kanya, Hsu, Hsue-Yin, Huang, Gloria S., Jensen, Lasse D., Jiang, Wen G., Jones, Lee W., Karpowicz, Phillip A., Nicol Keith, W., Kerkar, Sid P., Khan, Gazala N., Khatami, Mahin, Ko, Young H., Kucuk, Omer, Kulathinal, Rob J., Kumar, Nagi B., Kwon, Byoung S., Le, Anne, Lea, Michael A., Lee, Ho-Young, Lichtor, Terry, Lin, Liang-Tzung, Locasale, Jason W., Lokeshwar, Bal L., Longo, Valter D., Lyssiotis, Costas A., MacKenzie, Karen L., Malhotra, Meenakshi, Marino, Maria, Martinez-Chantar, Maria L., Matheu, Ander, Maxwell, Christopher, McDonnell, Eoin, Meeker, Alan K., Mehrmohamadi, Mahya, Mehta, Kapil, Michelotti, Gregory A., Mohammad, Ramzi M., Mohammed, Sulma I., James Morre, D., Muqbil, Irfana, Muralidhar, Vinayak, Murphy, Michael P., Purnachandra Nagaraju, Ganji, Nahta, Rita, Niccolai, Elena, Nowsheen, Somaira, Panis, Carolina, Pantano, Francesco, Parslow, Virginia R., Pawelec, Graham, Pedersen, Peter L., Poore, Brad, Poudyal, Deepak, Prakash, Satya, Prince, Mark, Raffaghello, Lizzia, Rathmell, Jeffrey C., Kimryn Rathmell, W., Ray, Swapan K., Reichrath, Joerg, Rezazadeh, Sarallah, Ribatti, Domenico, Ricciardiello, Luigi, Brooks Robey, R., Rodier, Francis, Vasantha Rupasinghe, H. P., Luigi Russo, Gian, Ryan, Elizabeth P., Samadi, Abbas K., Sanchez-Garcia, Isidro, Sanders, Andrew J., Santini, Daniele, Sarkar, Malancha, Sasada, Tetsuro, Saxena, Neeraj K., Shackelford, Rodney E., Shantha Kumara, H. M. C., Sharma, Dipali, Shin, Dong M., Sidransky, David, David Siegelin, Markus, Signori, Emanuela, Singh, Neetu, Sivanand, Sharanya, Sliva, Daniel, Smythe, Carl, Spagnuolo, Carmela, Stafforini, Diana M., Stagg, John, Subbarayan, Pochi R., Sundin, Tabetha, Talib, Wamidh H., Thompson, Sarah K., Tran, Phuoc T., Ungefroren, Hendrik, Vander Heiden, Matthew G., Venkateswaran, Vasundara, Vinay, Dass S., Vlachostergios, Panagiotis J., Wang, Zongwei, Wellendx, Kathryn E., Whelan, Richard L., Yang, Eddy S., Yang, Huanjie, Yang, Xujuan, Yaswen, Paul, Yedjou, Clement, Yin, Xin, Zhu, Jiyue, Zollo, Massimo, Block, Keith I., Gyllenhaal, Charlotte, Lowe, Leroy, Amedei, Amedeo, Ruhul Amin, A. R. M., Amin, Amr, Aquilano, Katia, Arbiser, Jack, Arreola, Alexandra, Arzumanyan, Alla, Salman Ashraf, S., Azmi, Asfar S., Benencia, Fabian, Bhakta, Dipita, Bilsland, Alan, Bishayeen, Anupam, Blain, Stacy W., Block, Penny B., Boosani, Chandra S., Carey, Thomas E., Carnero, Amancio, Carotenuto, Marianeve, Casey, Stephanie C., Chakrabarti, Mrinmay, Chaturvedi, Rupesh, Zhuo Chen, Georgia, Chenx, Helen, Chen, Sophie, Charlie Chen, Yi, Choi, Beom K., Rosa Ciriolo, Maria, Coley, Helen M., Collins, Andrew R., Connell, Marisa, Crawford, Sarah, Curran, Colleen S., Dabrosin, Charlotta, Damia, Giovanna, Dasgupta, Santanu, DeBerardinis, Ralph J., Decker, William K., Dhawan, Punita, Diehl, Anna Mae E., Dong, Jin-Tang, Ping Dou, Q., Drew, Janice E., Elkord, Eyad, El-Rayes, Bassel, Feitelson, Mark A., Felsher, Dean W., Ferguson, Lynnette R., Fimognari, Carmela, Firestone, Gary L., Frezza, Christian, Fujii, Hiromasa, Fuster, Mark M., Generali, Daniele, Georgakilas, Alexandros G., Gieseler, Frank, Gilbertson, Michael, Green, Michelle F., Grue, Brendan, Guha, Gunjan, Halicka, Dorota, Helferich, William G., Heneberg, Petr, Hentosh, Patricia, Hirschey, Matthew D., Hofseth, Lorne J., Holcombe, Randall F., Honoki, Kanya, Hsu, Hsue-Yin, Huang, Gloria S., Jensen, Lasse D., Jiang, Wen G., Jones, Lee W., Karpowicz, Phillip A., Nicol Keith, W., Kerkar, Sid P., Khan, Gazala N., Khatami, Mahin, Ko, Young H., Kucuk, Omer, Kulathinal, Rob J., Kumar, Nagi B., Kwon, Byoung S., Le, Anne, Lea, Michael A., Lee, Ho-Young, Lichtor, Terry, Lin, Liang-Tzung, Locasale, Jason W., Lokeshwar, Bal L., Longo, Valter D., Lyssiotis, Costas A., MacKenzie, Karen L., Malhotra, Meenakshi, Marino, Maria, Martinez-Chantar, Maria L., Matheu, Ander, Maxwell, Christopher, McDonnell, Eoin, Meeker, Alan K., Mehrmohamadi, Mahya, Mehta, Kapil, Michelotti, Gregory A., Mohammad, Ramzi M., Mohammed, Sulma I., James Morre, D., Muqbil, Irfana, Muralidhar, Vinayak, Murphy, Michael P., Purnachandra Nagaraju, Ganji, Nahta, Rita, Niccolai, Elena, Nowsheen, Somaira, Panis, Carolina, Pantano, Francesco, Parslow, Virginia R., Pawelec, Graham, Pedersen, Peter L., Poore, Brad, Poudyal, Deepak, Prakash, Satya, Prince, Mark, Raffaghello, Lizzia, Rathmell, Jeffrey C., Kimryn Rathmell, W., Ray, Swapan K., Reichrath, Joerg, Rezazadeh, Sarallah, Ribatti, Domenico, Ricciardiello, Luigi, Brooks Robey, R., Rodier, Francis, Vasantha Rupasinghe, H. P., Luigi Russo, Gian, Ryan, Elizabeth P., Samadi, Abbas K., Sanchez-Garcia, Isidro, Sanders, Andrew J., Santini, Daniele, Sarkar, Malancha, Sasada, Tetsuro, Saxena, Neeraj K., Shackelford, Rodney E., Shantha Kumara, H. M. C., Sharma, Dipali, Shin, Dong M., Sidransky, David, David Siegelin, Markus, Signori, Emanuela, Singh, Neetu, Sivanand, Sharanya, Sliva, Daniel, Smythe, Carl, Spagnuolo, Carmela, Stafforini, Diana M., Stagg, John, Subbarayan, Pochi R., Sundin, Tabetha, Talib, Wamidh H., Thompson, Sarah K., Tran, Phuoc T., Ungefroren, Hendrik, Vander Heiden, Matthew G., Venkateswaran, Vasundara, Vinay, Dass S., Vlachostergios, Panagiotis J., Wang, Zongwei, Wellendx, Kathryn E., Whelan, Richard L., Yang, Eddy S., Yang, Huanjie, Yang, Xujuan, Yaswen, Paul, Yedjou, Clement, Yin, Xin, Zhu, Jiyue, and Zollo, Massimo
- Abstract
Targeted therapies and the consequent adoption of "personalized" oncology have achieved notable successes in some cancers; however, significant problems remain with this approach. Many targeted therapies are highly toxic, costs are extremely high, and most patients experience relapse after a few disease-free months. Relapses arise from genetic heterogeneity in tumors, which harbor therapy-resistant immortalized cells that have adopted alternate and compensatory pathways (i.e., pathways that are not reliant upon the same mechanisms as those which have been targeted). To address these limitations, an international task force of 180 scientists was assembled to explore the concept of a low-toxicity "broadspectrum" therapeutic approach that could simultaneously target many key pathways and mechanisms. Using cancer hallmark phenotypes and the tumor microenvironment to account for the various aspects of relevant cancer biology, interdisciplinary teams reviewed each hallmark area and nominated a wide range of high-priority targets (74 in total) that could be modified to improve patient outcomes. For these targets, corresponding low-toxicity therapeutic approaches were then suggested, many of which were phytochemicals. Proposed actions on each target and all of the approaches were further reviewed for known effects on other hallmark areas and the tumor microenvironment Potential contrary or procarcinogenic effects were found for 3.9% of the relationships between targets and hallmarks, and mixed evidence of complementary and contrary relationships was found for 7.1%. Approximately 67% of the relationships revealed potentially complementary effects, and the remainder had no known relationship. Among the approaches, 1.1% had contrary, 2.8% had mixed and 62.1% had complementary relationships. These results suggest that a broad-spectrum approach should be feasible from a safety standpoint. This novel approach has potential to be relatively inexpensive, it should help us address s, Funding Agencies|Terry Fox Foundation Grant [TF-13-20]; UAEU Program for Advanced Research (UPAR) [31S118]; NIH [AR47901, R21CA188818, R15 CA137499-01, F32CA177139, P20RR016477, P20GM103434, R01CA170378, U54CA149145, U54CA143907, R01-HL107652, R01CA166348, R01GM071725, R01 CA109335-04A1, 109511R01CA151304CA168997 A11106131R03CA1711326 1P01AT003961RO1 CA100816P01AG034906 R01AG020642P01AG034906-01A1R01HL108006]; NIH NRSA Grant [F31CA154080]; NIH (NIAID) R01: Combination therapies for chronic HBV, liver disease, and cancer [AI076535]; Sky Foundation Inc. Michigan; University of Glasgow; Beatson Oncology Centre Fund; Spanish Ministry of Economy and Competitivity, ISCIII [PI12/00137, RTICC: RD12/0036/0028]; FEDER from Regional Development European Funds (European Union), Consejeria de Ciencia e Innovacion [CTS-6844, CTS-1848]; Consejeria de Salud of the Junta de Andalucia [PI-0135-2010, PI-0306-2012]; ISCIII [PIE13/0004]; FEDER funds; United Soybean Board; NIH NCCAM Grant [K01AT007324]; NIH NCI Grant [R33 CA161873-02]; Michael Cuccione Childhood Cancer Foundation Graduate Studentship; Ovarian and Prostate Cancer Research Trust, UK; West Virginia Higher Education Policy Commission/Division of Science Research; National Institutes of Health; Italian Association for Cancer Research (AIRC) [IG10636, 15403]; GRACE Charity, UK; Breast Cancer Campaign, UK; Michael Cuccione Childhood Cancer Foundation Postdoctoral Fellowship; Connecticut State University; Swedish Research Council; Swedish Research Society; University of Texas Health Science Centre at Tyler, Elsa U. Pardee Foundation; CPRIT; Cancer Prevention and Research Institute of Texas; NIH National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH National Institute on Alcohol Abuse and Alcoholism (NIAAA); Gilead and Shire Pharmaceuticals; NIH/NCI [1R01CA20009, 5R01CAl27258-05, R21CA184788, NIH P30 CA22453, NCI RO1 28704]; Scottish Governments Rural and Environment Science and Analytical Services Divis
- Published
- 2015
- Full Text
- View/download PDF
41. CCL2 and CCL5 Are Novel Therapeutic Targets for Estrogen-Dependent Breast Cancer
- Author
-
Svensson, Susanne, Abrahamsson, Annelie, Rodriguez, Gabriela Vazquez, Olsson, Anna-Karin, Jensen, Lasse, Cao, Yihai, Dabrosin, Charlotta, Svensson, Susanne, Abrahamsson, Annelie, Rodriguez, Gabriela Vazquez, Olsson, Anna-Karin, Jensen, Lasse, Cao, Yihai, and Dabrosin, Charlotta
- Abstract
Purpose: Novel therapeutic targets of estrogen receptor (ER)-positive breast cancers are urgently needed because current antiestrogen therapy causes severe adverse effects, nearly 50% of patients are intrinsically resistant, and the majority of recurrences have maintained ER expression. We investigated the role of estrogen-dependent chemokine expression and subsequent cancer growth in human tissues and experimental breast cancer models. Experimental Design: For in vivo sampling of human chemokines, microdialysis was used in breast cancers of women or normal human breast tissue before and after tamoxifen therapy. Estrogen exposure and targeted therapies were assessed in immune competent PyMT murine breast cancer, orthotopic human breast cancers in nude mice, cell culture of cancer cells, and freshly isolated human macrophages. Cancer cell dissemination was investigated using zebrafish. Results: ER+ cancers in women produced high levels of extracellular CCL2 and CCL5 in vivo, which was associated with infiltration of tumor-associated macrophages. In experimental breast cancer, estradiol enhanced macrophage influx and angiogenesis through increased release of CCL2, CCL5, and vascular endothelial growth factor. These effects were inhibited by anti-CCL2 or anti-CCL5 therapy, which resulted in potent inhibition of cancer growth. In addition, estradiol induced a protumorigenic activation of the macrophages. In a zebrafish model, macrophages increased cancer cell dissemination via CCL2 and CCL5 in the presence of estradiol, which was inhibited with anti-CCL2 and anti-CCL5 treatment. Conclusions: Our findings shed new light on the mechanisms underlying the progression of ER+ breast cancer and indicate the potential of novel therapies targeting CCL2 and CCL5 pathways. (C)2015 AACR.
- Published
- 2015
- Full Text
- View/download PDF
42. Tissue specific expression of extracellular microRNA in human breast cancers and normal human breast tissue in vivo
- Author
-
Abrahamsson, Annelie, Dabrosin, Charlotta, Abrahamsson, Annelie, and Dabrosin, Charlotta
- Abstract
Extracellular circulating microRNAs (miRNAs) have been suggested to be biomarkers for disease monitoring but data are inconsistent, one reason being that blood miRNA is of heterogeneous origin. Here, we sampled extracellular microRNAs locally in situ using microdialysis. Three different cohorts of women were included; postmenopausal women with ongoing breast cancer investigated within the cancer and in normal adjacent breast tissue, postmenopausal women investigated in their normal healthy breast and subcutaneous fat before and after six weeks of tamoxifen therapy, premenopausal women during the menstrual cycle. Samples were initially screened using TaqMan array cards with subsequently absolute quantification. 124 miRNA were expressed in microdialysates. After absolute quantifications extracellular miRNA-21 was found to be significantly increased in breast cancer. In addition, the levels were significantly higher in pre-menopausal breast tissue compared with postmenopausal. In breast tissue of pre-menopausal women miRNA-21 exhibited a cyclic variation during the menstrual cycle and in postmenopausal women six weeks of tamoxifen treatment decreased miRNA-21 suggesting that this miRNA may be important for breast carcinogenesis. None of these changes were found in plasma or microdialysates from subcutaneous fat. Our data revealed tissue specific changes of extracellular circulating miRNAs that would be otherwise unraveled using blood samples., Funding Agencies|Swedish Cancer Society [2012/454]; Swedish Research Council [2013-2457]; Linkoping University
- Published
- 2015
- Full Text
- View/download PDF
43. An overview of pregnancy and fertility issues in breast cancer patients
- Author
-
Dabrosin, Charlotta and Dabrosin, Charlotta
- Abstract
Breast cancer is one of the most common malignancies of women in the reproductive years. In the Western world there is a trend towards delaying pregnancy to later in life, and in combination with an increased incidence of breast cancer an increased number of women are diagnosed with breast cancer before they have completed their reproductive plans. In addition, breast cancer during pregnancy may affect an increased number of women as the childbearing years are delayed. The survival rate after breast cancer has improved during the last decades, and many young breast cancer survivors will consider a pregnancy subsequent to the completion of adjuvant breast cancer therapy. Traditionally, many women are advised against a pregnancy due to a fear of increased risk of recurrence, especially women with estrogen receptor-positive breast cancer. Due to feasibility issues, evidence from large prospective randomized trials is missing regarding the safety of pregnancy after breast cancer. Today guidelines are based on cohort studies and population-based registry evidence with its limitations. Overall, data suggest that pregnancy after breast cancer therapy is safe, and the current evidence is summarized in this overview.
- Published
- 2015
- Full Text
- View/download PDF
44. Neutrophils Promote Breast Cancer Progression and Metastasis via LFA-1 Integrin
- Author
-
Vazquez Rodriguez, Gabriela, Abrahamsson, Annelie, Jensen, Lasse, Dabrosin, Charlotta, Vazquez Rodriguez, Gabriela, Abrahamsson, Annelie, Jensen, Lasse, and Dabrosin, Charlotta
- Abstract
Cancer is considered an inflammatory condition where immune cells play an important role in progression and metastasis. Neutrophils may be pro- or antitumorigenic, depending on their phenotype or the number of infiltrating neutrophils in the tumor microenvironment. Massive infiltration of neutrophils in cancer tissue may elicit a cytotoxic effect, leading to tumor regression, whereas a S139 low-grade neutrophil gradient is tumor progressive. Chemokines, cytokines, and growth factors present in the tumor microenvironment, as well as cell-cell interactions mediated by integrins have shown to be determinant steps for cancer cells to break through the endothelial wall and establish metastatic niches. In this work we evaluated the role of lymphocyte functionassociated antigen 1 (LFA-1) integrin in neutrophils-mediated metastasis of estrogen receptor positive breast cancer cells (MCF-7) cells in a tumor xenograft model in zebrafish and in neutrophil infiltration in MCF-7 mammospheres. The metastatic capability of MCF-7 cells was evaluated in presence or absence of human neutrophils and with/without estradiol treatment. Two days old zebrafish embryos were injected into the perivitelline space with labeled MCF-7 cells and human neutrophils, an anti-human LFA-1 antibody (CD11a) was included. We show that estradiol treatment significantly increased the infiltration of neutrophils into MCF-7 mammospheres and this infiltration was significantly reduced by the presence of an anti-human CD11a antibody. Co-injection of MCF-7 cells with neutrophils significantly increased the migration of MCF-7 cells to distant sites in zebrafish and this effect was inhibited by using an anti-human CD11a antibody. We conclude that neutrophils affect the dissemination of breast cancer cells via LFA-1 integrin. Although estradiol increased the number of infiltrating neutrophils into mammospheres exposure to estradiol seemed to have minor effects on the dissemination in the zebrafish.
- Published
- 2015
- Full Text
- View/download PDF
45. Inflammation induced by mmp-9 enhances tumor regression of experimental breast cancer
- Author
-
Leifler, Karin Söderlund, Svensson, Susanne, Abrahamsson, Annelie, Bendrik, Christina, Robertson, Jennifer, Gauldie, Jack, Olsson, Anna-Karin, Dabrosin, Charlotta, Leifler, Karin Söderlund, Svensson, Susanne, Abrahamsson, Annelie, Bendrik, Christina, Robertson, Jennifer, Gauldie, Jack, Olsson, Anna-Karin, and Dabrosin, Charlotta
- Abstract
Matrix metalloproteinases (MMPs) have been suggested as therapeutic targets in cancer treatment, but broad-spectrum MMP inhibitors have failed in clinical trials. Recent data suggest that several MMPs including MMP-9 exert both pro- and antitumorigenic properties. This is also the case of the natural inhibitors of MMPs, tissue inhibitor of metalloproteinases (TIMPs). The inhibitor of MMP-9 is TIMP-1, and high levels of this enzyme have been associated with decreased survival in breast cancer. Inflammation is one hallmark of cancer progression, and MMPs/TIMPs may be involved in the local immune regulation. We investigated the role of MMP-9/TIMP-1 in regulating innate antitumor immunity in breast cancer. Breast cancers were established in nude mice and treated with intratumoral injections of adenoviruses carrying the human TIMP-1 or MMP-9 gene (AdMMP-9). In vivo microdialysis for sampling of cancer cell-derived (human) and stroma-derived (murine) proteins, immunostainings, as well as cell cultures were performed. We report a dose-dependent decrease of tumor growth and angiogenesis after AdMMP-9 treatment. In addition to increased generation of endostatin, AdMMP-9 promoted an antitumor immune response by inducing massive neutrophil infiltration. Neutrophil depletion prior to gene transfer abolished the therapeutic effects of AdMMP-9. Additionally, AdMMP-9 activated tumor-infiltrating macrophages into a tumor-inhibiting phenotype both in vivo and in vitro. AdMMP-9 also inhibited tumor growth in immune-competent mice bearing breast cancers. Adenoviruses carrying the human TIMP-1 gene had no effect on tumor growth or the immune response. Our novel data identify MMP-9 as a potent player in modulating the innate immune response into antitumor activities.
- Published
- 2013
- Full Text
- View/download PDF
46. Inflammation Induced by MMP-9 Enhances Tumor Regression of Experimental Breast Cancer
- Author
-
Söderlund, Karin, Svensson, Susanne, Abrahamsson, Annelie, Bendrik, Christina, Robertson, Jennifer, Gauldie, Jack, Olsson, Anna-Karin, Dabrosin, Charlotta, Söderlund, Karin, Svensson, Susanne, Abrahamsson, Annelie, Bendrik, Christina, Robertson, Jennifer, Gauldie, Jack, Olsson, Anna-Karin, and Dabrosin, Charlotta
- Abstract
Matrix metalloproteinases (MMPs) have been suggested as therapeutic targets in cancer treatment, but broad-spectrum MMP inhibitors have failed in clinical trials. Recent data suggest that several MMPs including MMP-9 exert both pro-and antitumorigenic properties. This is also the case of the natural inhibitors of MMPs, tissue inhibitor of metalloproteinases (TIMPs). The inhibitor of MMP-9 is TIMP-1, and high levels of this enzyme have been associated with decreased survival in breast cancer. Inflammation is one hallmark of cancer progression, and MMPs/TIMPs may be involved in the local immune regulation. We investigated the role of MMP-9/TIMP-1 in regulating innate antitumor immunity in breast cancer. Breast cancers were established in nude mice and treated with intratumoral injections of adenoviruses carrying the human TIMP-1 or MMP-9 gene (AdMMP-9). In vivo microdialysis for sampling of cancer cell-derived (human) and stroma-derived (murine) proteins, immunostainings, as well as cell cultures were performed. We report a dose-dependent decrease of tumor growth and angiogenesis after AdMMP-9 treatment. In addition to increased generation of endostatin, AdMMP-9 promoted an antitumor immune response by inducing massive neutrophil infiltration. Neutrophil depletion prior to gene transfer abolished the therapeutic effects of AdMMP-9. Additionally, AdMMP-9 activated tumor-infiltrating macrophages into a tumor-inhibiting phenotype both in vivo and in vitro. AdMMP-9 also inhibited tumor growth in immune-competent mice bearing breast cancers. Adenoviruses carrying the human TIMP-1 gene had no effect on tumor growth or the immune response. Our novel data identify MMP-9 as a potent player in modulating the innate immune response into antitumor activities. The Journal of Immunology, 2013, 190: 4420-4430., Funding Agencies|Swedish Cancer Society|2009/799|Swedish Research Council|2010-3458|Research Funds of Linkoping University Hospital
- Published
- 2013
- Full Text
- View/download PDF
47. Estradiol, Tamoxifen, and Flaxseed Alter IL-1 beta and IL-1Ra Levels in Normal Human Breast Tissue in Vivo
- Author
-
Abrahamsson, Annelie, Morad, Vivian, Saarinen, Niina M, Dabrosin, Charlotta, Abrahamsson, Annelie, Morad, Vivian, Saarinen, Niina M, and Dabrosin, Charlotta
- Abstract
Introduction: Sex steroid exposure increases the risk of breast cancer by unclear mechanisms. Diet modifications may be one breast cancer prevention strategy. The proinflammatory cytokine family of IL-1 is implicated in cancer progression. IL-1Ra is an endogenous inhibitor of the proinflammatory IL-1 alpha and IL-1 beta. less thanbrgreater than less thanbrgreater thanObjective: The objective of this study was to elucidate whether estrogen, tamoxifen, and/or diet modification altered IL-1 levels in normal human breast tissue. less thanbrgreater than less thanbrgreater thanDesign and Methods: Microdialysis was performed in healthy women under various hormone exposures, tamoxifen therapy, and diet modifications and in breast cancers of women before surgery. Breast tissue biopsies from reduction mammoplasties were cultured. less thanbrgreater than less thanbrgreater thanResults: We show a significant positive correlation between estradiol and in vivo levels of IL-1 beta in breast tissue and abdominal sc fat, whereas IL-1Ra exhibited a significant negative correlation with estradiol in breast tissue. Tamoxifen or a dietary addition of 25 g flaxseed per day resulted in significantly increased levels of IL-1Ra in the breast. These results were confirmed in ex vivo culture of breast biopsies. Immunohistochemistry of the biopsies did not reveal any changes in cellular content of the IL-1s, suggesting that mainly the secreted levels were affected. In breast cancer patients, intratumoral levels of IL-1 beta were significantly higher compared with normal adjacent breast tissue. less thanbrgreater than less thanbrgreater thanConclusion: IL-1 may be under the control of estrogen in vivo and may be attenuated by antiestrogen therapy and diet modifications. The increased IL-1 beta in breast cancers of women strongly suggests IL-1 as a potential therapeutic target in breast cancer treatment and prevention., Funding Agencies|Swedish Cancer Society|2009/799|Swedish Research Council|2010-3458|Research Funds of Linkoping University Hospital
- Published
- 2012
- Full Text
- View/download PDF
48. Tamoxifen and Flaxseed Alter Angiogenesis Regulators in Normal Human Breast Tissue In Vivo
- Author
-
Nilsson, Ulrika, Saarinen, Niina, Abrahamsson, Annelie, Nurmi, Tarja, Engblom, Sofia, Dabrosin, Charlotta, Nilsson, Ulrika, Saarinen, Niina, Abrahamsson, Annelie, Nurmi, Tarja, Engblom, Sofia, and Dabrosin, Charlotta
- Abstract
The incidence of breast cancer is increasing in the Western world and there is an urgent need for studies of the mechanisms of sex steroids in order to develop novel preventive strategies. Diet modifications may be among the means for breast cancer prevention. Angiogenesis, key in tumor progression, is regulated by the balance between pro-and anti-angiogenic factors, which are controlled in the extracellular space. Sampling of these molecules at their bioactive compartment is therefore needed. The aims of this study were to explore if tamoxifen, one of the most used anti-estrogen treatments for breast cancer affected some of the most important endogenous angiogenesis regulators, vascular endothelial growth factor (VEGF), angiogenin, and endostatin in normal breast tissue in vivo and if a diet supplementation with flaxseed had similar effects as tamoxifen in the breast. Microdialysis was used for in situ sampling of extracellular proteins in normal breast tissue of women before and after six weeks of tamoxifen treatment or before and after addition of 25 g/day of ground flaxseed to the diet or in control women. We show significant correlations between estradiol and levels of VEGF, angiogenin, and endostatin in vivo, which was verified in ex vivo breast tissue culture. Moreover, tamoxifen decreased the levels of VEGF and angiogenin in the breast whereas endostatin increased significantly. Flaxseed did not alter VEGF or angiogenin levels but similar to tamoxifen the levels of endostatin increased significantly. We conclude that one of the mechanisms of tamoxifen in normal breast tissue include tipping of the angiogenic balance into an anti-angiogenic state and that flaxseed has limited effects on the pro-angiogenic factors whereas the anti-angiogenic endostatin may be modified by diet. Further studies of diet modifications for breast cancer prevention are warranted., Funding Agencies|Swedish Cancer Society||Swedish Research Counsil||Ekhaga Foundation||Academy of Finland|114526115459
- Published
- 2011
- Full Text
- View/download PDF
49. Tamoxifen, Flaxseed, and the Lignan Enterolactone Increase Stroma- and Cancer Cell-Derived IL-1Ra and Decrease Tumor Angiogenesis in Estrogen-Dependent Breast Cancer
- Author
-
Lindahl, Gabriel, Saarinen, Niina, Abrahamsson, Annelie, Dabrosin, Charlotta, Lindahl, Gabriel, Saarinen, Niina, Abrahamsson, Annelie, and Dabrosin, Charlotta
- Abstract
The proinflammatory cytokines IL-1 alpha and IL-1 beta promote tumor angiogenesis that might be counteracted by the IL-1 receptor antagonist (IL-1Ra), anakinra, a clinically approved agent. A diet with high amounts of phytoestrogens, such as flaxseed (Flax), genistein (GEN), and the mammalian lignan enterolactone (ENL), may affect breast cancer progression in a similar fashion as the antiestrogen tamoxifen. Both cancer cells and tumor stroma may be targets for cancer therapy. By using microdialysis in a model of human breast cancers in nude mice, we could perform species-specific analyses of released proteins in the microenvironment. We show that tumors treated with tamoxifen and fed Flax or ENL exhibited decreased in vivo release of IL-1 beta derived from the murine stroma and decreased microvessel density whereas dietary GEN had no effects. Cancer cell-released IL-1Ra were approximately 5 times higher than stroma-derived IL-1Ra. Tamoxifen, Flax, and ENL increased IL-1Ra levels significantly whereas GEN did not. The tumor stroma contained macrophages, which expressed the estrogen receptor. In vitro, estradiol decreased IL-1Ra released from breast cancer cells and from cultured macrophages. IL-1Ra decreased endothelial cell proliferation significantly in vitro whereas breast cancer cell proliferation was unaffected in presence of estradiol. Finally, IL-1Ra therapy of tumor-bearing mice opposed estrogen-dependent breast cancer growth and decreased angiogenesis. We conclude that the release of IL-1s both by cancer cells and the stroma, where macrophages are a key component, may offer feasible targets for antiestrogen therapy and dietary interventions against breast cancer.
- Published
- 2011
- Full Text
- View/download PDF
50. Angiogenin Regulation by Estradiol in Breast Tissue: Tamoxifen Inhibits Angiogenin Nuclear Translocation and Antiangiogenin Therapy Reduces Breast Cancer Growth In vivo
- Author
-
Nilsson, Ulrika, Abrahamsson, Annelie, Dabrosin, Charlotta, Nilsson, Ulrika, Abrahamsson, Annelie, and Dabrosin, Charlotta
- Abstract
Purpose: Angiogenin, a 14.2-kDa polypeptide member of the RNase A superfamily, has potent angiogenic effects. Nuclear accumulation of angiogenin is essential for its angiogenic activity. Increased angiogenin expression has been associated with the transition of normal breast tissue into invasive breast carcinoma. In this article, we investigated whether estradiol (E-2) affected angiogenin in breast tissue. Experimental Design: We used microdialysis for sampling of extracellular angiogenin in vivo. In vitro cultures of whole normal breast tissue, breast cancer cells, and endothelial cells were used. Results: We show that extracellular angiogenin correlated significantly with E-2 in normal human breast tissue in vivo and that exposure of normal breast tissue biopsies to E-2 stimulated angiogenin secretion. In breast cancer patients, the in vivo angiogenin levels were significantly higher in tumors compared with the adjacent normal breast tissue. In estrogen receptor-positive breast cancer cells, E-2 increased and tamoxifen decreased angiogenin secretion. Moreover, E-2-induced angiogenin derived from cancer cells significantly increased endothelial cell proliferation. Tamoxifen reversed this increase as well as inhibited nuclear translocation of angiogenin. In vivo, in experimental breast cancer, tamoxifen decreased angiogenin levels and decreased angiogenesis. Additionally, treating tumor-bearing mice with an antiangiogenin antibody resulted in tumor stasis, suggesting a role for angiogenin in estrogen-dependent breast cancer growth. Conclusion: Our results suggest previously unknown mechanisms by which estrogen and antiestrogen regulate angiogenesis in normal human breast tissue and breast cancer. This may be important for estrogen-driven breast cancer progression and a molecular target for therapeutic interventions.
- Published
- 2010
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.